Ankylosing spondylitis

Ankylosing Spondylitis Associated with Increased Risk of Blood Clot Condition

Retrieved on: 
Wednesday, February 13, 2019
Medical specialties, Medicine, Rheumatology, Arthritis, RTT, Autoimmune diseases, Aging-associated diseases, Ankylosing spondylitis, Rheumatoid arthritis, Spondylitis, Knee arthritis, Psoriatic arthritis

VTE is rare but potentially life-threatening and an increased risk of the condition has been demonstrated in other types of inflammatory arthritis, including psoriatic and rheumatoid arthritis.

Key Points: 
  • VTE is rare but potentially life-threatening and an increased risk of the condition has been demonstrated in other types of inflammatory arthritis, including psoriatic and rheumatoid arthritis.
  • But there is very little evidence of its risk in patients with ankylosing spondylitis.
  • "These results call for awareness of this complication, increased vigilance and preventive intervention by controlling the inflammatory process or by anticoagulation in a high-risk ankylosing spondylitis population," Dr. Avia-Zubieta said.
  • "We now need to study whether or not inflammation-decreasing treatment could reduce the risk of this condition."

Global Ankylosing Spondylitis Market and Competitive Landscape 2014-2018 & 2023

Retrieved on: 
Tuesday, November 6, 2018
Medicine, Rheumatology, Clinical medicine, Ankylosing spondylitis, Arthritis, RTT, TNF inhibitors, Spondylitis, Bimekizumab, Axial spondyloarthritis

The "Global Ankylosing Spondylitis Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Ankylosing Spondylitis Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.
  • Global Ankylosing Spondylitis Market and Competitive Landscape - 2018, provides comprehensive insights into Ankylosing Spondylitis pipeline, epidemiology, market valuations, product sales, market forecast, product forecasts, and market shares.
  • The research is classified into following sections - Ankylosing Spondylitis overview with definitions, symptoms, etiology, diagnosis, treatment options; Ankylosing Spondylitis pipeline insights covering late stage clinical trials pipeline; Ankylosing Spondylitis prevalence trends by countries; Ankylosing Spondylitis market size and forecast by countries, market events, trends; product sales and forecast by countries; market shares by countries.
  • Ankylosing Spondylitis pipeline: Find out the drugs in clinical trials for Ankylosing Spondylitis by stages, phase 3 clinical trials, phase 2 clinical trials, and phase 1 clinical trials, by pharmacological class, by company
    Ankylosing Spondylitis epidemiology: Find out the prevalence of Ankylosing Spondylitis by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan; prevalence forecast to 2023
    Ankylosing Spondylitis products: Identify key products marketed and prescribed for Ankylosing Spondylitis by brand name, by molecule, by company, by branded / generic, by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan
    Ankylosing Spondylitis market size: Find out the market size for Ankylosing Spondylitis drugs by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan; Find out how the market advanced from 2014
    Ankylosing Spondylitis drug sales: Find out the sales of Ankylosing Spondylitis drugs by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan, Global
    Ankylosing Spondylitis drugs sales forecast: Sales forecast for Ankylosing Spondylitis drugs to 2023 by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan
    Ankylosing Spondylitis market share analysis: Find out the market shares of Ankylosing Spondylitis drugs and outlook by countries - US, Europe, Germany, France, Italy, Spain, UK, Japan
    Did you know that we also offer Custom Research?

ACR 2018: Lilly Announces Positive Results for Two Phase 3 Studies of Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)

Retrieved on: 
Monday, October 22, 2018
Medicine, Clinical medicine, Monoclonal antibodies, Immunosuppressants, Immunology, Rheumatology, Clinical research, TNF inhibitors, Ankylosing spondylitis, Ixekizumab, Adalimumab, BASDAI

The analyses are part of a clinical development program that aims to evaluate Taltz (ixekizumab) across various populations of patients with AS.

Key Points: 
  • The analyses are part of a clinical development program that aims to evaluate Taltz (ixekizumab) across various populations of patients with AS.
  • COAST-V, which included 341 patients, is the first Phase 3 study of Taltz among patients with AS who had never received a biologic disease-modifying anti-rheumatic drug (bDMARD).
  • It also is the first study to include both a placebo control arm and active reference arm (adalimumab).
  • BASDAI50: 42 percent of patients treated with Taltz every four weeks, 43 percent of patients treated with Taltz every two weeks and 17 percent of patients treated with placebo achieved a Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50).

Digital Landscape: Ankylosing Spondylitis

Retrieved on: 
Monday, October 1, 2018
Economy, Rheumatology, Online advertising, Ankylosing spondylitis, Arthritis, RTT, HCPS, Digital strategy, Business

LONDON, Oct. 1, 2018 /PRNewswire/ -- Digital Landscape: Ankylosing Spondylitis

Key Points: 
  • LONDON, Oct. 1, 2018 /PRNewswire/ -- Digital Landscape: Ankylosing Spondylitis
    - The report includes digital activities directed towards patients and/or HCPs.
  • - The report includes digital activities directed towards patients and/or HCPs, including branded websites, unbranded disease awareness initiatives, social media and mobile apps.
  • - Our Digital Landscape report provides an analysis of pharma multichannel activity in the digital AS space, and can assist our pharma clients derive value in a number of ways.
  • - Digital Strategy: Strengthen corporate digital excellence, learn from industry best practice, and identify opportunities for novel digital campaigns
    - Support new brand launch: See best practice examples of pre- and post-launch digital activities, ascertain must-have digital assets for patient and HCP engagement, and assess potential gaps and opportunities for pipeline brands
    - Business Development & Licensing: Assess topics and trends shaping digital health in AS and beyond, and learn about key patient and physician online activities in AS.

PEGylated Protein Therapeutics Market Worth $17,813 Million by 2025 | CAGR: 6.9% - Allied Market Research

Retrieved on: 
Monday, August 13, 2018
Medicine, RTT, Rheumatology, Health, Biotechnology, Clinical medicine, PEGylation, Pharmacokinetics, Ankylosing spondylitis, Arthritis

PEGylated protein therapeutics are used in multiple conditions such as cancer, hemophilia, rheumatoid arthritis, ankylosing spondylitis, Crohns disease, and others.

Key Points: 
  • PEGylated protein therapeutics are used in multiple conditions such as cancer, hemophilia, rheumatoid arthritis, ankylosing spondylitis, Crohns disease, and others.
  • Europe is anticipated to occupy one-fifth market share of the global PEGylated protein therapeutics market by 2025.
  • Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon.
  • Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions."

Musculoskeletal Disorders Pipeline Database 2018: Osteoporosis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Ankylosing Spondylitis

Retrieved on: 
Wednesday, April 18, 2018
Medicine, RTT, Rheumatology, Arthritis, Anatomy, Health, Skeletal disorders, Autoimmune diseases, Rheumatism, Osteoarthritis, Ankylosing spondylitis, Rheumatoid arthritis

Musculoskeletal Disorders Pipeline Highlights Database - 2018, provides most up-to-date information on key pipeline products in the global Musculoskeletal Disorders market.

Key Points: 
  • Musculoskeletal Disorders Pipeline Highlights Database - 2018, provides most up-to-date information on key pipeline products in the global Musculoskeletal Disorders market.
  • Key indications covered in this database include Osteoarthritis, Osteoporosis, Rheumatoid Arthritis, Systemic lupus erythematosus, and Ankylosing Spondylitis.
  • Key indications covered in this database include Osteoarthritis, Osteoporosis, Rheumatoid Arthritis, Systemic lupus erythematosus, and Ankylosing Spondylitis.
  • The database provides Musculoskeletal Disorders pipeline products by the company.